ROTH Capital Partners to Host Innovations in Oncology Corporate Access Day in New York on November 17, 2016

Event to Feature One-on-One Meetings Between Institutional Investors and Senior Management Teams Representing Companies Focused in the Oncology and Targeted Therapeutic Companies

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--ROTH Capital Partners (ROTH), www.roth.com, a full service investment bank focused on serving emerging growth companies and their investors, today announced that it will host its Innovations in Oncology Corporate Access Day on Thursday, November 17, 2016 at the Lotte New York Palace in New York City.

ROTH’s Innovations in Oncology Corporate Access Day will give investors the opportunity to interact with senior management of a select group of Oncology and Targeted Therapeutics companies. There will also be a keynote luncheon with Oncology expert Sotirios G. Stergiopoulos, MD, MBEE, Vice President and Head of Global Medical Affairs Oncology at SHIRE.

The event will allow for extensive interaction and 1-on-1 meetings with management teams, providing in-depth insights into each company.

ROTH biotechnology research analysts Joe Pantginis, Ph.D., Michael Higgins and Mark Breidenbach, Ph.D., will be available to discuss their perspectives regarding the companies attending and their views regarding the current biotechnology market trends.

“Oncology continues to represent a significant unmet medical need, despite many recent revolutionary advances such as the immune checkpoint inhibitors. As the industry pushes well beyond the old mainstays of chemotherapy and radiation into targeted and personalized therapies, major insights continue to be learned about combination approaches,” says Joe Pantginis, Ph.D, Senior Biotechnology Research Analyst at ROTH. “These companies we are hosting represent, in our belief, a set of companies with cutting edge technologies, as well as attractive market caps for investors who look to take part in oncology investment. Innovations in Oncology are attracting broad interest in the investment community, physicians, and drug companies, and we expect the trend to continue as more positive data read out.”

“Given the rapid developments and changing dynamics in this sector, our objective of this corporate access day is to provide investors with direct interactions with management teams of a select group of leading Oncology companies,” commented John W. Chambers, Vice Chairman and Head of Healthcare Investment Banking at ROTH. “These companies will be available for 1-on-1 meetings with investors to present their technology, clinical development strategies, clinical achievements to date and upcoming milestones and catalysts. The event is intended to enable investors to gain direct insight into the key value drivers for this group of innovative companies.”

ROTH has built a leading Healthcare Investment Banking Group over the last several years and has raised approximately $12 billion in over 340 Healthcare transactions since 2010. *Past Performance is not indicative of future returns. (Source: ROTH Capital Partners | 11/03/2016)

The event is for institutional clients of ROTH and is by invitation only. For more information, please contact your ROTH sales representative at [phone] or e-mail: [e-mail]

Thursday | November 17, 2016
8:00 am - 9:00 am | Registration and Morning Coffee
8:45 am - 9:00 am | Introduction by ROTH Senior Research Analysts
9:00 am - 4:45 pm | 1-on-1 / Small Group Meetings
12:00 pm - 1:00 pm | Luncheon with Oncology expert Sotirios G. Stergiopoulos, MD, MBEE

Venue | Hotel
Lotte New York Palace
455 Madison Avenue
New York City, NY 10022 | Tel: [phone]

Participating Companies
The following participating companies are confirmed as of the date of this release (as of 11/02/2016)

Aduro BioTech, Inc. (ADRO)
Argos Therapeutics, Inc. (ARGS)
Celldex Therapeutics, Inc. (CLDX)
Fate Therapeutics, Inc. (FATE)
Fortress Biotech, Inc. (FBIO)
Lion Biotechnologies, Inc. (LBIO)
MacroGenics, Inc. (MGNX)
Nektar Therapeutics (NKTR)
Pieris Pharmaceuticals, Inc. (PIRS)
Sorrento Therapeutics, Inc. (SRNE )
StemlineTherapeutics, Inc. (STML)
Syndax Pharmaceuticals, Inc. (SNDX)
TG Therapeutics, Inc (TGTX)
VBL Therapeutics (VBLT)
Viralytics Ltd (VLA)

Event sponsors include Equisolve, Ellenoff Grossman & Schole LLP and Business Wire.

About ROTH Capital Partners, LLC:

ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and maintains offices throughout the U.S. For more information on ROTH, please visit www.roth.com.